Select market-stage ATMPs price in the U.S. as of 2016

This statistic shows the price of select market-stage ATMPs, as of September 2016. At that moment, the price of ex-vivo gene therapy Strimvelis stood at 665,000 U.S. dollars.

Price of select market-stage advanced therapy medicinal products (ATMPs) as of 2016

Product name (product type)Price in U.S. dollars
Glybera (in vivo gene therapy)*1,250,000
Strimvelis (ex vivo gene therapy)665,000
Prochymal (allogeneic MSCs for GvHD)200,000
Temcell (allogeneic GvHD adjuvant)*142,500
Provenge (autologous dendritic cell cancer vaccine)93,000
Cartistem (allogeneic MSC chondrocyte repair)*30,000
ChondroCelect (autologous chondrocyte cell therapy)24,000
Hearticellgram (autologous MSCs for AMI)19,000
Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in

Release date

December 2017



Survey time period

as of September 2016

Supplementary notes

* Mean value.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Cell and gene therapy"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.